» Articles » PMID: 34368166

Identification of Somatic Mutation-Driven Immune Cells by Integrating Genomic and Transcriptome Data

Overview
Specialty Cell Biology
Date 2021 Aug 9
PMID 34368166
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor somatic mutations in protein-coding regions may generate neoantigens which may trigger antitumor immune cell response. Increasing evidence supports that immune cell response may profoundly influence tumor progression. However, there are no calculated tools to systematically identify immune cells driven by specific somatic mutations. It is urgent to develop a calculated method to comprehensively detect tumor-infiltrating immune cells driven by the specific somatic mutations in cancer. We developed a novel software package (SMDIC) that enables the automated identification of somatic mutation-driven immune cell. SMDIC provides a novel pipeline to discover mutation-specific immune cells by integrating genomic and transcriptome data. The operation modes include inference of the relative abundance matrix of tumor-infiltrating immune cells, detection of differential abundance immune cells with respect to the gene mutation status, conversion of the abundance matrix of significantly dysregulated cells into two binary matrices (one for upregulated and one for downregulated cells), identification of somatic mutation-driven immune cells by comparing the gene mutation status with each immune cell in the binary matrices across all samples, and visualization of immune cell abundance of samples in different mutation status for each gene. SMDIC provides a user-friendly tool to identify somatic mutation-specific immune cell response. SMDIC may contribute to understand the mechanisms underlying anticancer immune response and find targets for cancer immunotherapy. The SMDIC was implemented as an R-based tool which was freely available from the CRAN website https://CRAN.R-project.org/package=SMDIC.

Citing Articles

Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures.

Li J, Wu J, Han J Genes (Basel). 2023; 14(1).

PMID: 36672784 PMC: 9858482. DOI: 10.3390/genes14010044.


Development and Validation of a Three-Gene Prognostic Signature Based on Tumor Microenvironment for Gastric Cancer.

Wang Q, Li X, Wang Y, Qiu J, Wu J, He Y Front Genet. 2022; 12:801240.

PMID: 35178071 PMC: 8843853. DOI: 10.3389/fgene.2021.801240.

References
1.
Liu S, Dhar P, Wu J . NK Cell Plasticity in Cancer. J Clin Med. 2019; 8(9). PMC: 6780970. DOI: 10.3390/jcm8091492. View

2.
Han J, Liu S, Jiang Y, Xu C, Zheng B, Jiang M . Inference of patient-specific subpathway activities reveals a functional signature associated with the prognosis of patients with breast cancer. J Cell Mol Med. 2018; 22(9):4304-4316. PMC: 6111825. DOI: 10.1111/jcmm.13720. View

3.
Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M . Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999; 190(5):617-27. PMC: 2195611. DOI: 10.1084/jem.190.5.617. View

4.
Han X, Kong Q, Liu C, Cheng L, Han J . SubtypeDrug: a software package for prioritization of candidate cancer subtype-specific drugs. Bioinformatics. 2021; 37(16):2491-2493. DOI: 10.1093/bioinformatics/btab011. View

5.
Robbins P, Lu Y, El-Gamil M, Li Y, Gross C, Gartner J . Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013; 19(6):747-52. PMC: 3757932. DOI: 10.1038/nm.3161. View